FDA Approves Pralsetinib for Locally Advanced, Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

FDA Approves Pralsetinib for Locally Advanced, Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

header-info

Aug, 10, 2023

On August 9, 2023, The US Food and Drug Administration (FDA) approved pralsetinib for adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.

Access the full article to read more here.